Patents Assigned to WATERSTONE PHARMACEUTICALS(WUHAN) CO., LTD.
  • WS-635 uses thereof in medicine
    Patent number: 12226446
    Abstract: The present invention relates to a method of treating, preventing, or lessening postoperative cognitive dysfunction (POCD) in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically effective amount of a compound of Formula I or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof,
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: February 18, 2025
    Assignees: WATERSTONE PHARMACEUTICALS(WUHAN) CO., LTD., THE GENERAL HOSPITAL CORPORATION
    Inventors: Faming Zhang, Jian Cui, Yao Yu, Minglong Hu, Zhongcong Xie
  • Crystalline form of compound and uses thereof in medicine
    Patent number: 11993664
    Abstract: A crystalline form A of the compound having formula (I) and uses thereof in medicine are described. Specifically, it relates to crystalline form A and pharmaceutically compositions thereof. Furthermore, it relates to the uses of crystalline form A disclosed herein and pharmaceutically compositions thereof disclosed herein in the manufacture of a medicament, especially in the manufacture of a medicament for preventing, managing, treating or lessening hepatitis C vims (HCV) infection.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: May 28, 2024
    Assignee: WATERSTONE PHARMACEUTICALS(WUHAN) CO., LTD.
    Inventors: Jian Cui, Yao Yu, Minglong Hu
  • PHARMACEUTICAL POLYMER FOR TREATING HYPERKALEMIA AND PREPARATION METHOD THEREOF
    Publication number: 20240139234
    Abstract: Provided herein is a potassium-binding polymer prepared by polymerization reaction of a monomer and a crosslinking agent, wherein the monomer is the compound of formula (V), the crosslinking agent is the compound of formula (VI), and/or the compound of formula (VII), wherein the variables are as defined in the specification; to the use thereof for treating or preventing hyperkalemia.
    Type: Application
    Filed: November 4, 2021
    Publication date: May 2, 2024
    Applicant: WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD.
    Inventors: Min FU, Minglong HU, Tongtong LI, Ying LIANG, Xiaolong WANG, Yao YU, Faming ZHANG
  • Maleate of SCY-635 and uses thereof in medicine
    Patent number: 11845809
    Abstract: The present invention relates to a salt of a compound of formula (I) and uses thereof in medicine. Specifically, it relates to maleate of compound of formula (I) and pharmaceutically compositions thereof. Furthermore, the invention relates to the uses of maleate herein and pharmaceutically compositions thereof disclosed herein in the manufacture of a medicament, especially in the manufacture of a medicament for preventing, managing, treating or lessening hepatitis C virus (HCV) infection.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: December 19, 2023
    Assignee: WATERSTONE PHARMACEUTICALS(WUHAN) CO., LTD.
    Inventors: Jian Cui, Yao Yu, Minglong Hu
  • POLYMERS, COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA
    Publication number: 20230102864
    Abstract: The disclosure provides small molecule compounds, polymers, and compositions thereof, as well as methods for preparing such polymers and compositions. Also provided is a method of using the polymers or compositions thereof for binding uric acid or precursor thereof, and/or for treating hyperuricemia, gout, and/or diseases caused by hyperuricemia.
    Type: Application
    Filed: May 18, 2022
    Publication date: March 30, 2023
    Applicant: WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD.
    Inventors: Youcheng ZHOU, Tongtong LI, Minglong HU, Yan LI, Kang BIE, Ying LIANG, Jian CUI, Faming ZHANG
  • CRYSTALLINE FORM OF COMPOUND AND USES THEREOF IN MEDICINE
    Publication number: 20210324008
    Abstract: A crystalline form A of the compound having formula (I) and uses thereof in medicine are described. Specifically, it relates to crystalline form A and pharmaceutically compositions thereof. Furthermore, it relates to the uses of crystalline form A disclosed herein and pharmaceutically compositions thereof disclosed herein in the manufacture of a medicament, especially in the manufacture of a medicament for preventing, managing, treating or lessening hepatitis C vims (HCV) infection.
    Type: Application
    Filed: August 22, 2019
    Publication date: October 21, 2021
    Applicant: WATERSTONE PHARMACEUTICALS(WUHAN) CO., LTD.
    Inventors: Jian Cui, Yao Yu, Minglong Hu